In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ameren’s current price exceeds the PERT-weighted fair value by 34.8%, signaling potential overvaluation despite diversified valuation methods. Low financial health scores, especially in growth and liquidity, highlight operational challenges. Monte Carlo analysis shows negligible downside risk below the current price, implying price stability amid elevated valuation.